In addition, ivabradine has been reported to reduce the activation of JNK and p38 MAPK in various animal models; for example, a murine model of chronic viral myocarditis (Li et al., 2016) and a model of diabetic cardiomyopathy (Zuo et al., 2019). Here, MAPK8 is linked to diabetic cardiomyopathy.